Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03816163
Title A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Astellas Pharma Global Development, Inc.
Indications

pancreatic adenocarcinoma

Therapies

Gemcitabine + Nab-paclitaxel

Gemcitabine + Nab-paclitaxel + Zolbetuximab

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP


No variant requirements are available.